Thermo Fisher Scientific (TMO-NYSE)
Written by CEO & CIO, Bruce Murray, CFA.
Target US$650.00 – Return 21%
We recently added Thermo Fisher Scientific (TMO) to the Global Growth Portfolio. Having completed over 100 acquisitions since 2006, TMO has consolidated the highly fragmented life sciences tool & diagnostics (LST&Dx) industry.
In so doing, it has created a virtual one-stop shop for the tools required to develop new products for the biopharma industry. TMO’s products and services cover equipment and tools for the medical industry to the management of research and patient care. To fund the purchase, we sold our position in Intuitive Surgical (ISRG). As the chart below illustrates, ISRG (white) has massively outperformed TMO (blue) over the last year. Read